+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Optic Neuritis (Ophthalmology) - Drugs In Development, 2021

  • ID: 5438181
  • Report
  • August 2021
  • Region: Global
  • 57 Pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Accure Therapeutics SL
  • EnhanX Biopharm Inc
  • Meta-IQ ApS
  • ReNetX Bio
  • SanBio Co Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide 'Optic Neuritis - Drugs In Development, 2021', provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape. Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon and flashing lights. Risk factors include age and genetic mutations.

Report Highlights


This report provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 5 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Accure Therapeutics SL
  • EnhanX Biopharm Inc
  • Meta-IQ ApS
  • ReNetX Bio
  • SanBio Co Ltd
Introduction

Optic Neuritis - Overview

Optic Neuritis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Optic Neuritis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Optic Neuritis - Companies Involved in Therapeutics Development
  • Accure Therapeutics SL
  • EnhanX Biopharm Inc
  • Japan Innovative Therapeutics Inc
  • Meta-IQ ApS
  • Mitochon Pharmaceuticals Inc
  • Noveome Biotherapeutics Inc
  • ReNetX Bio
  • SanBio Co Ltd

Optic Neuritis - Drug Profiles
  • ACT-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AXER-204 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ENX-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • etomoxir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapies for Glaucoma, Optic Neuritis and Retinitis Pigmentosa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • gypenoside - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MP-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Optic Neuritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ST-266 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Optic Neuritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Optic Neuritis - Dormant Projects

Optic Neuritis - Discontinued Products

Optic Neuritis - Product Development Milestones

Featured News & Press Releases
  • Oct 21, 2020: Noveome Biotherapeutics announces publication of preclinical results demonstrating the neuroprotective properties of amnion-derived multipotent pCells in spinal cord and retinal ganglion cells
  • May 15, 2019: Bionure appoints Dr. Lucia Septien as chief medical officer
  • May 09, 2019: Noveome Biotherapeutics announces publication of further preclinical results supporting the neuroprotective properties of ST266 in retinal ganglion cells
  • May 07, 2019: Neuroprotection Biotech Bionure Reports Successful Phase 1 Study for Lead Candidate BN201
  • Oct 09, 2018: Bionure appoints Dr. Laurent Nguyen as CEO
  • May 16, 2018: Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom
  • Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Optic Neuritis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Optic Neuritis - Pipeline by Accure Therapeutics SL, 2021
  • Optic Neuritis - Pipeline by EnhanX Biopharm Inc, 2021
  • Optic Neuritis - Pipeline by Japan Innovative Therapeutics Inc, 2021
  • Optic Neuritis - Pipeline by Meta-IQ ApS, 2021
  • Optic Neuritis - Pipeline by Mitochon Pharmaceuticals Inc, 2021
  • Optic Neuritis - Pipeline by Noveome Biotherapeutics Inc, 2021
  • Optic Neuritis - Pipeline by ReNetX Bio, 2021
  • Optic Neuritis - Pipeline by SanBio Co Ltd, 2021
  • Optic Neuritis - Dormant Projects, 2021
  • Optic Neuritis - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Optic Neuritis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Accure Therapeutics SL
  • EnhanX Biopharm Inc
  • Japan Innovative Therapeutics Inc
  • Meta-IQ ApS
  • Mitochon Pharmaceuticals Inc
  • Noveome Biotherapeutics Inc
  • ReNetX Bio
  • SanBio Co Ltd
Note: Product cover images may vary from those shown